Virtus Investment Advisers LLC Has $413,000 Stake in Amicus Therapeutics, Inc. $FOLD

Virtus Investment Advisers LLC grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 103.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 72,025 shares of the biopharmaceutical company’s stock after purchasing an additional 36,655 shares during the quarter. Virtus Investment Advisers LLC’s holdings in Amicus Therapeutics were worth $413,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Mackenzie Financial Corp lifted its position in Amicus Therapeutics by 89.4% during the 1st quarter. Mackenzie Financial Corp now owns 42,605 shares of the biopharmaceutical company’s stock worth $348,000 after buying an additional 20,107 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Amicus Therapeutics by 177.1% in the first quarter. XTX Topco Ltd now owns 106,773 shares of the biopharmaceutical company’s stock worth $871,000 after acquiring an additional 68,245 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of Amicus Therapeutics during the first quarter worth approximately $1,533,000. PNC Financial Services Group Inc. lifted its position in shares of Amicus Therapeutics by 211.4% during the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 3,497 shares in the last quarter. Finally, Legacy Capital Group California Inc. grew its stake in shares of Amicus Therapeutics by 16.2% during the first quarter. Legacy Capital Group California Inc. now owns 26,993 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 3,764 shares during the last quarter.

Amicus Therapeutics Price Performance

FOLD stock opened at $9.94 on Friday. The stock has a 50-day moving average price of $8.79 and a two-hundred day moving average price of $7.39. The stock has a market cap of $3.07 billion, a PE ratio of -82.78 and a beta of 0.66. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $10.57.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.05. The company had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.Amicus Therapeutics’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. Amicus Therapeutics has set its FY 2025 guidance at EPS. Equities analysts forecast that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Analyst Ratings Changes

FOLD has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Tuesday. The Goldman Sachs Group upped their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. raised their price target on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.57.

Insider Buying and Selling at Amicus Therapeutics

In other news, insider Jeff Castelli sold 76,158 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $10.16, for a total value of $773,765.28. Following the sale, the insider owned 439,318 shares of the company’s stock, valued at $4,463,470.88. The trade was a 14.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 14,587 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $10.04, for a total transaction of $146,453.48. Following the transaction, the chief executive officer owned 1,137,282 shares of the company’s stock, valued at $11,418,311.28. The trade was a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 201,652 shares of company stock valued at $2,019,288 over the last ninety days. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.